Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-1001b in IDH1 Mutated Gliomas
NCT03030066Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2017
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of safusidenib in glioma, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Dose Limiting Toxicities at 21 days. Started Jan 2017; status: completed.
02
Drugs
safusidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03030066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030066.